

## Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

### Listing of Claims:

Claims 1-27 (cancelled).

Claim 28 (currently amended): A method for providing for the take of a graft to a mammal in need thereof, the method comprising:

- a) providing the graft from one or more of the group consisting of a suitable donor, cultured epidermal cells, acellular dermal matrix, cellular matrix, skin and mucosa,
- b) ~~contacting~~ applying a ~~non-mineralized tissue recipient bed or lesion with a~~ prophylactically effective amount of an active enamel substance to a non-mineralized tissue recipient bed or lesion, and
- c) placing the graft on the ~~pre-treated~~ non-mineralized tissue recipient bed or lesion.

Claim 29 (previously presented): A method according to claim 28, wherein the active enamel substance is applied in an amount of total protein per cm of graft bed area corresponding to from about 0.1 mg/cm<sup>2</sup> to about 15 mg/cm<sup>2</sup>.

Claim 30 (previously presented): A method according to claim 28, wherein the active enamel substance is applied on the recipient bed or lesion before application of the graft described in step c.

Claim 31 (previously presented): A method according to claim 30, wherein the active enamel substance is applied for a period of up to 72 hours before the application of the graft.

Claim 32 (previously presented): A method according to claim 28, wherein the graft is a skin graft or mucosal graft.

Claim 33 (previously presented): A method according to claim 28, wherein the graft is an autogenous skin graft.

Claim 34 (previously presented): A method according to claim 28, wherein the graft is a full-thickness, split-thickness, composite, seed or mesh graft.

Claim 35 (currently amended): A method according to claim 28, wherein the graft comprises cultured epidermal cells.

Claims 36-40 (cancelled).

Claim 41 (previously presented): A method according to claim 28, wherein the active enamel substance is enamel matrix, enamel matrix proteins, derivatives thereof, or mixtures thereof.

Claim 42 (previously presented): A method according to claim 28, wherein the active enamel substance is selected from the group consisting of enamelines, amelogenins, non-amelogenins, proline-rich amelogenins, amelins, tuftelins, mixtures thereof, and derivatives of said substances.

Claim 43 (previously presented): A method according to claim 28, wherein the active enamel substance has a molecular weight of up to about 120 kDa as determined by SDS Page electrophoresis.

Claim 44 (previously presented): A method according to claim 28, wherein the active enamel substance has a molecular weight of up to about 100 kDa as determined by SDS Page electrophoresis.

Claim 45 (previously presented): A method according to claim 28, wherein the active enamel substance has a molecular weight of up to about 60 kDa as determined by SDS Page electrophoresis.

Claim 46 (previously presented): A method according to claim 28, wherein the active enamel substance contains a mixture of active enamel substances with different molecular weights.

Claim 47 (previously amended): A method according to claim 28, wherein the preparation of an active enamel substance comprises at least one substance selected from the group consisting of amelogenins, proline-rich non-amelogenins, tuftelins, tuft proteins, serum proteins, salivary proteins, amelin, ameloblastin, sheathlin, mixtures thereof, and derivatives thereof.

Claim 48 (previously presented): A method according to claim 28, wherein the active enamel substance has a molecular weight of between about 5,000 and about 25,000.

Claim 49 (previously presented): A method according to claim 28, wherein the major part of the active enamel substance has a molecular weight of about 20 kDa.

Claim 50 (previously presented): A method according to claim 28, wherein at least a part of the active enamel substance is in the form of aggregates or after application in vivo is capable of forming aggregates.

Claim 51 (previously presented): A method according to claim 50, wherein the aggregates have a particle size of from about 20 nm to about 1  $\mu\text{m}$ .

Claim 52 (previously presented): A method according to claim 28, wherein the protein content of the active enamel substance in the preparation is in a range of from about 0.05% w/w to 100% w/w.

Claim 53 (previously presented): A method according to claim 28, wherein the protein content of the active enamel substance in the preparation is in a range of from about 30-90% w/w.

Claim 54 (previously presented): A method according to claim 28, wherein a pharmaceutical or cosmetic composition comprising an active enamel substance and a pharmaceutically acceptable excipient is in step b) administered to the mammalian recipient bed or lesion.

Claim 55 (previously amended): A method according to claim 54, wherein the pharmaceutically acceptable excipient is propylene glycol alginate.

Claims 56-65 (cancelled).